To the best of our knowledge, our study is the first to demonstrate that patients with invasive NFPAs had significantly higher percentage of peripheral CD8+ Tregs than patients with noninvasive NFPAs and healthy controls and lower tumor infiltration of CD28+ cells than patients with noninvasive NFPAs. This evidence concerns the gene CD8A and neoplasm.